Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 13;7(1):13.
doi: 10.1186/s41181-022-00165-0.

Synthesis of a 2-nitroimidazole derivative N-(4-[18F]fluorobenzyl)-2-(2-nitro-1H-imidazol-1-yl)-acetamide ([18 F]FBNA) as PET radiotracer for imaging tumor hypoxia

Affiliations

Synthesis of a 2-nitroimidazole derivative N-(4-[18F]fluorobenzyl)-2-(2-nitro-1H-imidazol-1-yl)-acetamide ([18 F]FBNA) as PET radiotracer for imaging tumor hypoxia

Arian Pérez Nario et al. EJNMMI Radiopharm Chem. .

Abstract

Background: Tissue hypoxia is a pathological condition characterized by reducing oxygen supply. Hypoxia is a hallmark of tumor environment and is commonly observed in many solid tumors. Non-invasive imaging techniques like positron emission tomography (PET) are at the forefront of detecting and monitoring tissue hypoxia changes in vivo.

Results: We have developed a novel 18F-labeled radiotracer for hypoxia PET imaging based on cytotoxic agent benznidazole. Radiotracer N-(4-[18F]fluorobenzyl)-2-(2-nitro-1H-imidazol-1-yl)acetamide ([18F]FBNA) was synthesized through acylation chemistry with readily available 4-[18F]fluorobenzyl amine. Radiotracer [18F]FBNA was obtained in good radiochemical yields (47.4 ± 5.3%) and high radiochemical purity (> 95%). The total synthesis time was 100 min, including HPLC purification and the molar activity was greater than 40 GBq/µmol. Radiotracer [18F]FBNA was stable in saline and mouse serum for 6 h. [18F]FBNA partition coefficient (logP = 1.05) was found to be more lipophilic than [18F]EF-5 (logP = 0.75), [18F]FMISO (logP = 0.4) and [18F]FAZA (logP = - 0.4). In vitro studies showed that [18F]FBNA accumulates in gastric cancer cell lines AGS and MKN45 under hypoxic conditions.

Conclusions: Hence, [18F]FBNA represents a novel and easy-to-prepare PET radioligand for imaging hypoxia.

Keywords: Hypoxia; N-(4-[18F]fluorobenzyl)-2-(2-nitro-1H-imidazol-1-yl)acetamide ([18F]FBNA); Positron emission tomography (PET).

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Chemical structures of selected 18F-labeled 2-nitroimidazoles used for PET imaging of tissue hypoxia
Fig. 2
Fig. 2
Chemical structures of benznidazole and [18F]FBNA
Scheme 1
Scheme 1
Synthesis of the labeling precursor 3 and reference compound 4. Reagents and conditions: (a) CH3CO2CH2CH2Br, K2CO3, CH3CN, rt, 21 h; (b) 4.0 N NaOH, H2O/MeOH, rt, 3 h; (c) 4-Fluorobenzylamine, trifluoroacetic acid anhydride, THF, 0 °C, 1 h
Scheme 2
Scheme 2
Radiosynthesis of [18F]FBNA from its precursor, 2-nitroimidazole acetic acid (3)
Fig. 3
Fig. 3
Radio-HPLC traces of the reaction ([18F]FBNA: tR. = 15.1 ± 0.3 min) performed at room temperature (A), 65 °C (B), 85 °C (C) and 100 °C (D)
Fig. 4
Fig. 4
HPLC traces of [18F]FBNA (left) ([18F]FBNA: tR. = 15.1 ± 0.3 min) and reference compound FBNA (right) (FBNA: tR. = 15.0 ± 0.3 min). UV detector was installed ahead of radioactivity detector
Fig. 5
Fig. 5
Radio-HPLC traces obtained after the incubation of [18F]FBNA (tR: 15.2 min) at (A) the initial time (t = 0 min), (B) physiological saline solution (NaCl 0.9%) after 6 h or (C) mouse serum after 6 h
Fig. 6
Fig. 6
In vitro uptake assay. AGS and MKN45 cells were seeded in a 6-well plate and cultured for 48 h under normoxic (21% O2) or hypoxic (1% of O2) for 48 h. After this period, 0.37 MBq of (A) [18F]FBNA or (B) [18F]FAZA was incubated for 1 h. Bars show the mean ± standard deviation (SD) of the uptake of the radiotracer (cpm)/2 × 105 cells of three independent experiments (n = 3). Data were analyzed by one unpaired t-test (multiple t tests); *p < 0.5, ****p < 0.0001 (Holm-Sidak method)
Fig. 7
Fig. 7
Characteristic of hypoxic PET tracers under development and number of clinical trials

Similar articles

Cited by

References

    1. Ali R, Apte S, Vilalta M, Subbarayan M, Miao Z, Chin FT, Graves EE. 18F-EF5 PET is predictive of response to fractionated radiotherapy in preclinical tumor models. PLoS ONE. 2015;10:139–43. - PMC - PubMed
    1. Askoxylakis V, Dinkel J, Eichinger M, Stieltjes B, Sommer G, Strauss LG, Dimitrakopoulou SA, Schneider AK, Haberkorn U, Huber PEL, Bischof M, Debus J, Thieke C. Multimodal hypoxia imaging and intensity modulated radiation therapy for unresectable non-small-cell lung cancer: the HIL trial. Radiat Oncol. 2012;7:157. doi: 10.1186/1748-717X-7-157. - DOI - PMC - PubMed
    1. Barker HE, Paget JTE, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015;15:409–425. doi: 10.1038/nrc3958. - DOI - PMC - PubMed
    1. Barthel H, Wilson H, Collingridge DR, et al. In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography. Br J Cancer. 2004;90:2232–2242. doi: 10.1038/sj.bjc.6601862. - DOI - PMC - PubMed
    1. Bern C, Montgomery SP, Herwaldt BL, Anis R, Dantas RO, Maguire JH, Acquatella H, Morillo C, Kirchhoff LV, Gilman RH, Reyes PA, Salvatella R, Moore AC. Evaluation and treatment of chagas disease in the United States: a systematic review. JAMA. 2007;298:2171–2181. doi: 10.1001/jama.298.18.2171. - DOI - PubMed

LinkOut - more resources